CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 400 enrolled
Drug / intervention
liraglutide +3 moredrug
Likely dose
liraglutide 0.9 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00393718
NCT00393718Phase 3Completed
CompareCT.gov

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Oct 30, 2006·Updated Mar 8, 2017

In Brief

A Phase 3 clinical trial evaluating liraglutide, glibenclamide, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 400 participants across 1 site.

Detailed Summary

This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after 24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2006
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2007
Study CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.7 years ago

Interventions

liraglutidedrug

0.9 mg/day. Injected s.c. (under the skin) once daily.

glibenclamidedrug

1.25-2.5 mg tablet. Given orally once or twice daily.

placebodrug

liraglutide placebo. Injected s.c. (under the skin) once daily.

placebodrug

glibenclamide placebo. Given orally once or twice daily.